Neuralink

Fremont, CA · Founded 2016 · Privately Held (backing)

Developer of an implantable brain-machine interface designed to help people with paralysis. Neuralink is based in Fremont, CA and was founded in 2016. It is valued at about $59.8 billion as of Oct 2026, set by secondary market price, up 520% since its Series E in Jun 2025. It has raised $1.3 billion across 7 recorded rounds; the latest was a private secondary transaction in Feb 2026.

PMV mark · valuation
$59.8B
Oct 2026
Secondary market · $/share
$311
Total raised
$1.3B
Last round
Secondary Transaction - Private
Feb 2026

Neuralink key facts

as of Oct 2026
  • Developer of an implantable brain-machine interface designed to help people with paralysis.
  • Neuralink is valued at approximately $59.8B (~$311/share on the secondary market) as of Oct 2026, up 520% since its Series E, Jun 2025, per PrivateMarketView’s mark.
  • It has raised $1.3B across 7 recorded rounds; the latest was Secondary Transaction - Private in Feb 2026.
  • Notable investors include Oman Investment Authority, Sequoia Capital, Lightspeed Venture Partners, GV, Team Ignite Ventures — 88 tracked in total.
  • 2 institutional filers report fund marks on Neuralink across 10 filings.
  • PrivateMarketView tracks 36 recorded secondary trades in Neuralink shares.
  • 1 investment vehicle was formed to buy Neuralink shares in the last 12 months, per SEC Form D filings.
  • Neuralink has filed 6 Form Ds with the SEC since 2017, most recently Jun 2025 ($649.0M sold to 49 investors).
PrivateMarketView mark
MEDIUM confidence
$59.8B~$311 per share · secondary market

Up 520% since its Series E, Jun 2025 ($9.7B post-money).

set by secondary market priceconfirmed by printsround price disagreeas of Oct 2026question about this number?
See the prints behind this mark →

Membership and data by Private Market View

Free account
More of Neuralink with a free account
  • ·Post-money valuations for 6 rounds
  • ·The complete investor list: 88 names
  • ·Everyone on the team, board and advisors included
  • ·Watch Neuralink: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Secondary market

monthly marks · 46 months · Jan 2023 – Oct 2026
Current
▮
High
▮
Low
▮
▮▮
Jan 2023marks: indicative $/share, month-end · as of Oct 15, 2026Oct 2026
Monthly marks are a Pro feature — the shape is real, the numbers are waiting.Unlock 46 monthly marks

Membership and data by Private Market View

Neuralink secondary trades

36 on record · Aug 2022 – May 2026

36 trades between Aug 2022 and May 2026. Exact dates, prices and structures are available to Pro members.

Aug 2022peak 5 prints / monthMay 2026
Individual prints are Pro.Unlock 36 trade prints

Membership and data by Private Market View

Institutional fund marks on Neuralink

2 filers · latest Jul 2026

2 SEC-registered funds reported 10 fair-value marks on Neuralink between Jun 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.

Unlock 10 fund marks

Membership and data by Private Market View

Every name the funds mark, next to where it trades →

Neuralink funding rounds

7 rounds
Feb 2026Secondary Transaction - Private—▮
Jun 2025Series E$650.0M▮
Nov 2023Series D$323.2M▮
Jul 2021Series C$205.9M▮
Jun 2019Series B$51.0M▮

Vehicles formed to buy Neuralink shares

secondary demand · SEC Form D filings

In the last 12 months, 1 investment vehicle were formed to buy Neuralink shares. Most recent filing Jun 2026.

The vehicle list — each sponsor, filing date, amount sold and investor count — is a Pro table. Unlock the 1 vehicle →

Membership and data by Private Market View

Neuralink leadership

Neuralink valuation

Neuralink is valued at approximately $59.8 billion as of Oct 2026. The figure is set by secondary market price and confirmed by prints. The secondary market quotes about $311 per share. The reference point is its Series E in Jun 2025, at a $9.7 billion post-money valuation; the current figure is up 520% since.

Neuralink ranks 7th by valuation and 29th by capital raised among the private companies PrivateMarketView tracks.

Recent activity

In the last 90 days, Neuralink's record added 1 institutional fund mark (latest period Jul 2026).

How much has Neuralink raised?

Neuralink has raised $1.3 billion across 7 recorded rounds since 2017. The largest was a $650 million Series E in Jun 2025; the most recent was a private secondary transaction in Feb 2026. 6 of the rounds disclosed a post-money valuation.

Neuralink has filed 6 Form Ds with the SEC since 2017, most recently in Jun 2025 ($649 million sold to 49 investors).

Neuralink secondary market activity

36 secondary trades in Neuralink shares are on record, between Aug 2022 and May 2026. The busiest recent months were Apr 2026 (5 prints) and Jul 2025 (4 prints). Exact dates, prices and structures are available to Pro members.

A monthly secondary-market price series for Neuralink runs from Jan 2023 to Oct 2026 (46 months).

Institutional holders and vehicles

2 SEC-registered funds reported 10 fair-value marks on Neuralink between Jun 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

In the last 12 months, 1 investment vehicle was formed to buy Neuralink shares, per SEC Form D filings (most recent Jun 2026).

Neuralink investors

88 investors are on record for Neuralink, including Oman Investment Authority, Sequoia Capital, Lightspeed Venture Partners and GV. By type, the record holds 54 venture capital firms, 4 family offices and 3 growth equity firms. 1 of them led a round. The private secondary transaction in Feb 2026 drew 1 investor.

Who runs Neuralink

6 people are listed on the Neuralink team: 6 executives, including Dongjin Seo (Co-Founder) and Elon Musk (Co-Founder). 6 of them have a verified direct contact on file.

About Neuralink

Developer of an implantable brain-machine interface designed to help people with paralysis. The company's interface treats and diagnoses neurological conditions in humans and, conceivably, augments human cognitive powers, enabling doctors to treat serious brain diseases in the short term.

Sector
Biotechnology
HQ
Fremont, CA, United States
Founded
2016
Employees
492
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.